• Belite Bio scheduled oral presentations at Euretina meetings in Vienna, including Phase 3 DRAGON topline results for tinlarebant in adolescent Stargardt disease.
• Results have not yet been presented; the Phase 3 readout is set for Oct. 4, 2026.
• The update is positioned as a pivotal trial outcome that could shape tinlarebant’s development path in inherited retinal disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609282000PRIMZONEFULLFEED9835528) on September 29, 2026, and is solely responsible for the information contained therein.